Correct, let's add BOD to the story. They have 1.7k prescriptions and are listed in early 2017 on the ASX they still can't keep up with Althea.
I am looking at the financials and they are worse off.
For AGH cashflow from operating activities is improving, customer base and SAS is much higher than any other cannabis companies.
CEO has the largest % of holdings in the company and has vested 5M of options to be granted by September 2020 if he reaches 2M revenue and some other conditions. You can find this in the annual report.
Everyone has financial metrics ahead and targets, including Greg with the so hated acquisition of "Peak Processing".
Ummm I forgot spending 30M on a production faculty that has to make 25M Revenue and 12.5 EBITDA within 18 months is bad,
but spending 180M on Mandura production facility like CAN did is much better. With 0 customers in the pipeline.
Guys remember if Greg doesn't reach the targets he doesn't get any shares from Althea and tbh If I see Althea with 25M revenue within 18 months from now it's a screaming buy for me. DYOR
It's not even worth wasting my time to explain facts to members who spam the threads and haven't even read 1 full annual report.
